Powered by

Zydus gets DCGI approval for phase-3 clinical trials of Covid-19 therapy

Dec 04, 2020 - Business Standard India

Trials will involve use of Cadila's biological therapy Pegylated Interferon alpha-2b in India Cadila Healthcare Ltd (Zydus Cadila) has obtained approval from the Drugs Controller General of India (DCGI) to start the phase-3 clinical trial on Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. Last month, Zydus Cadila had announced "successful" completion of phase two clinical trial of the biological therapy on Covid-19 patients, paving way for ph...